Epineuron has enrolled the first patient in a trial investigating its PeriPulse device for the treatment of acute peripheral nerve injury.
The Ontario, Canada-based company plans to enrol a total of 110 patients across Canada and the US in the study called REGAIN, in what it calls the largest medical device study for nerve regeneration.
PeriPulse is a temporary peripheral nerve stimulation system. It delivers electrical impulses directly to the damaged nerve either during surgery or shortly after. The therapy works by promoting neurotrophic factors which activate growth-associated gene expression.
